Content about Perrigo Co.

April 1, 2013

Perrigo Co. has completed its acquisition of a Pennsylvania-based animal health company, the drug maker said.

ALLEGAN, Mich. — Perrigo Co. has completed its acquisition of a Pennsylvania-based animal health company, the drug maker said Monday.

Perrigo announced that it has closed its purchase of Yardley, Pa.-based Velcera for about $160 million. The company makes OTC products for pets, specializing in products traditionally dispensed only by veterinarians. Its products include PetArmor, a flea and tick repellent that had sales of more than $100 million last year.

February 4, 2013

Perrigo launches generic scalp medicine

Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.

ALLEGAN, Mich. — Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.

Perrigo announced the launch of clobetasol emulsion propionate foam in the 0.05% strength, a generic version of GlaxoSmithKline's Olux-E. The drug is used to treat moderate to severe dermatosis of the scalp.

November 28, 2012

FDA approves Perrigo, Cobrek scalp psoriasis treatment

The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

Perrigo said that Cobrek, with which it is partnering, had received approval for betamethasone validate foam in the 0.12% strength. The drug is a generic version of Luxiq foam, made by GlaxoSmithKline subsidiary Stiefel Labs, and is used to treat corticosteroid-responsive skin conditions of the scalp, also known as scalp psoriasis.

The branded version of the drug has annual sales of about $40 million, according to Perrigo.

September 7, 2012

Perrigo seeks approval for generic bronchospasm drug

Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.

ALLEGAN, Mich. — Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.

August 8, 2012

FDA approves morphine sulfate oral solution

The Food and Drug Administration has approved an oral painkiller made by Perrigo, the drug maker said Wednesday.

ALLEGAN, Mich. — The Food and Drug Administration has approved an oral painkiller made by Perrigo, the drug maker said Wednesday.

Perrigo announced the approval of morphine sulfate oral solution in the 100-mL/5% strength. The drug is a Schedule II controlled substance and is used to treat moderate to severe acute and chronic pain. Sales of the drug are about $26 million per year, according to Wolters Kluwer Health. Perrigo said it would ship the drug immediately.

June 27, 2012

FDA approves Perrigo acne treatment

The Food and Drug Administration has approved an acne treatment made by Perrigo, the drug maker said Wednesday.

ALLEGAN, Mich. — The Food and Drug Administration has approved an acne treatment made by Perrigo, the drug maker said Wednesday.

June 7, 2012

Perrigo wins approval for renal failure drug

The Food and Drug Administration has approved a drug for kidney disease made by Perrigo.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug for kidney disease made by Perrigo.

Perrigo announced the approval of calcium acetate capsules, a generic version of Nabi Biopharmaceuticals' Phoslo Gelcaps. The drug is used to treat end-stage renal failure.

Perrigo settled a patent infringement lawsuit concerning the drug last year, though terms of the settlement were not disclosed. Annual sales of the branded version of the drug and generic versions were $95 million, according to Wolters Kluwer Health.

May 23, 2012

FDA approves treatment for vaginal fungus infections

The Food and Drug Administration has approved a generic treatment made by Perrigo for fungal infections of the vagina, the company said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a generic treatment made by Perrigo for fungal infections of the vagina, the company said.

Perrigo announced the approval of butoconazole nitrate 2% vaginal cream, a generic version of KV Pharmaceutical's Gynazole-1, used to treat vulvovaginal candidiasis, an infection caused by Candida fungus. KV voluntarily discontinued selling the drug in January 2009 due to manufacturing problems.

March 2, 2012

Perrigo launches generic version of Rogaine 5% foam

Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam, which is a generic version of Rogaine 5% foam hair regrowth treatment, to its retail and wholesale customers. Minoxidil 5% foam is marketed under store- or own-label brands.

ALLEGAN, Mich. — Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam, which is a generic version of Rogaine 5% foam hair regrowth treatment, to its retail and wholesale customers. Minoxidil 5% foam is marketed under store- or own-label brands.

January 23, 2012

Perrigo files for approval of generic nasal allergy drug

Perrigo is seeking approval from the Food and Drug Administration for a drug used to treat allergies in adolescents and adults, the company said Monday.

ALLEGAN, Mich. — Perrigo is seeking approval from the Food and Drug Administration for a drug used to treat allergies in adolescents and adults, the company said Monday.

January 9, 2012

Perrigo buys CanAm Care

Drug maker Perrigo is buying a privately owned distributor of diabetes products, the company said Monday.

ALLEGAN, Mich. — Drug maker Perrigo is buying a privately owned distributor of diabetes products, the company said Monday.

Perrigo announced the $36 million acquisition of Alpharetta, Ga.-based CanAm Care, whose assets include Dex4 hypoglycemia products, insulin delivery syringes and pen needles, lancing, wound care and compression stockings.

November 3, 2011

FDA approves generic version of Merck's Elestat ophthalmic solution

The Food and Drug Administration has approved a drug made by Perrigo and PharmaForce/Luitpold Pharmaceuticals for treating eye allergies, Perrigo said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug made by Perrigo and PharmaForce/Luitpold Pharmaceuticals for treating eye allergies, Perrigo said.

The FDA approved epinastine hydrochloride ophthalmic solution in the 0.05% strength. The drug is a generic version of Merck's Elestat, used to treat ocular itching related to allergic conjunctivitis.

Annual sales for the branded version before the appearance of generics on the market were $30 million, according to Wolters Kluwer.

November 2, 2011

Perrigo seeks approval for generic version of Abbott's Androgel

Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

October 6, 2011

Perrigo receives tentative FDA approval for generic scalp dermatosis drug

The Food and Drug Administration has granted tentative approval to a drug made by Perrigo for dermatosis of the scalp.

ALLEGAN, Mich. — The Food and Drug Administration has granted tentative approval to a drug made by Perrigo for dermatosis of the scalp.

Perrigo's clobetasol propionate emulsion foam in the 0.05% strength is a generic version of Stiefel Labs' Olux-E Foam. Sales for the branded version of the drug were $40 million during the 12-month period ended in September, according to Wolters Kluwer.

August 30, 2011

FDA approves Perrigo, Cobrek dermatitis drug

The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

ALLEGAN, Mich. — The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

The drug maker said Tuesday that the FDA approved ketoconazole foam in the 2% strength. The drug is a generic version of Stiefel Labs' Extina, a topical drug used to treat seborrheic dermatitis in patients ages 12 years and older with healthy immune systems.

Extina has annual sales of about $10 million, according to Perrigo.